Alex­ion preps an FDA pitch on Soliris suc­ces­sor while sig­nal­ing more deals ahead for rare dis­ease drugs

Alex­ion used its Q1 up­date Thurs­day to un­veil an­oth­er set of Phase III non-in­fe­ri­or stats for its Soliris suc­ces­sor, adding to its reg­u­la­to­ry pack­age for new ap­provals that should ship lat­er this year.

Fol­low­ing ear­li­er proof of non-in­fe­ri­or­i­ty for treat­ment-naive pa­tients, the new Phase III high­light­ed their suc­cess­ful switch­ing of Soliris pa­tients to ALXN1210, a shift from dos­ing every two weeks to eight weeks.

Lud­wig Hantson

To be sure, the in­ves­ti­ga­tors un­der­scored the same kind of im­prove­ments they found over Soliris on key mea­sures, but there was noth­ing sta­tis­ti­cal­ly sig­nif­i­cant about it. That will be good for shoring up their de­fense of the fran­chise drug for years to come — com­pa­ny ex­ecs talked of patents stretch­ing out to 2035 — as ri­vals press along with new drugs they hope can beat the stan­dard ther­a­py for parox­ys­mal noc­tur­nal he­mo­glo­bin­uria (PNH).

Now the biotech is prep­ping reg­u­la­to­ry pitch­es that should ar­rive in a mat­ter of months.

Ear­li­er this month Alex­ion an­nounced a deal to buy a Stock­holm-based biotech for $855 mil­lion in cash, bag­ging a new drug for rare cas­es of Wil­son dis­ease. The com­pa­ny is us­ing that as a mod­el for more deals just like it.

Paul Clan­cy

CFO Paul Clan­cy not­ed:

I would char­ac­ter­ize the bias to­wards prod­ucts, not to­wards plat­forms. Nev­er say nev­er, but this is rare dis­ease. Wil­son rep­re­sents a good ex­am­ple of our bias. Rare dis­ease, dev­as­tat­ing dis­eases, a po­ten­tial prod­uct to trans­form the dis­ease, and we’re build­ing up our abil­i­ty to do that in­side the com­pa­ny.

CEO Lud­wig Hantson sought to re­as­sure an­a­lysts that they were sat­is­fied that they could con­vert a large num­ber of pa­tients to the new drug, which some an­a­lysts be­lieve will have to come with a dis­count for pay­ers. Dur­ing the call with an­a­lysts, the CEO said:

We have a dif­fer­en­ti­at­ed pro­file with 1210. I don’t think any­body will dis­pute that. And, for sure, we’re go­ing to try to get the best la­bel. And we be­lieve that the da­ta that we have will be re­flect­ed in the clin­i­cal tri­al sec­tion. The way I look at it, we don’t need the su­pe­ri­or­i­ty claim to be suc­cess­ful for a fast con­ver­sion. We have a strong, dif­fer­en­ti­at­ed clin­i­cal pro­file, a ro­bust da­ta pack­age.

It’s not ide­al, but an­a­lysts like Ge­of­frey Porges saw rea­sons for ap­plause.

Alex­ion not­ed that ‘1210 was nu­mer­i­cal­ly su­pe­ri­or on both the pri­ma­ry and all key sec­ondary end­points. We are al­so en­cour­aged by the dis­clo­sure that ze­ro sub­jects treat­ed with ‘1210 ex­pe­ri­enced break­through he­mol­y­sis ver­sus 5 sub­jects treat­ed with Soliris. In terms of safe­ty, there were no dis­con­tin­u­a­tions due to ad­verse events, neu­tral­iz­ing an­ti­bod­ies, or cas­es of meningo­coc­cal in­fec­tion.

Biotech Half­time Re­port: Af­ter a bumpy year, is biotech ready to re­bound?

The biotech sector has come down firmly from the highs of February as negative sentiment takes hold. The sector had a major boost of optimism from the success of the COVID-19 vaccines, making investors keenly aware of the potential of biopharma R&D engines. But from early this year, clinical trial, regulatory and access setbacks have reminded investors of the sector’s inherent risks.

RBC Capital Markets recently surveyed investors to take the temperature of the market, a mix of specialists/generalists and long-only/ long-short investment strategies. Heading into the second half of the year, investors mostly see the sector as undervalued (49%), a large change from the first half of the year when only 20% rated it as undervalued. Around 41% of investors now believe that biotech will underperform the S&P500 in the second half of 2021. Despite that view, 54% plan to maintain their position in the market and 41% still plan to increase their holdings.

How to col­lect and sub­mit RWD to win ap­proval for a new drug in­di­ca­tion: FDA spells it out in a long-await­ed guid­ance

Real-world data is messy. There can be differences in the standards used to collect different types of data, differences in terminologies and curation strategies, and even in the way data is exchanged.

While acknowledging this somewhat controlled chaos, the FDA is now explaining how biopharma companies can submit study data derived from real-world data (RWD) sources in applicable regulatory submissions, including new drug indications.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

David Livingston (Credit: Michael Sazel for CeMM)

Renowned Dana-Far­ber sci­en­tist, men­tor and bio­phar­ma ad­vi­sor David Liv­ingston has died

David Livingston, the Dana-Farber/Harvard Med scientist who helped shine a light on some of the key molecular drivers of breast and ovarian cancer, died unexpectedly last Sunday.

One of the senior leaders at Dana-Farber during his nearly half century of work there, Livingston was credited with shedding light on the genes that regulate cell growth, with insights into inherited BRCA1 and BRCA2 mutations that helped lay the scientific foundation for targeted therapies and earlier detection that have transformed the field.

David Lockhart, ReCode Therapeutics CEO

Pfiz­er throws its weight be­hind LNP play­er eye­ing mR­NA treat­ments for CF, PCD

David Lockhart did not see the meteoric rise of messenger RNA and lipid nanoparticles coming.

Thanks to the worldwide fight against Covid-19, mRNA — the genetic code that can be engineered to turn the body into a mini protein factory — and LNPs, those tiny bubbles of fat carrying those instructions, have found their way into hundreds of millions of people. Within the biotech world, pioneers like Alnylam and Intellia have demonstrated just how versatile LNPs can be as a delivery vehicle for anything from siRNA to CRISPR/Cas9.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 120,300+ biopharma pros reading Endpoints daily — and it's free.

No­vo CEO Lars Fruer­gaard Jør­gensen on R&D risk, the deal strat­e­gy and tar­gets for gen­der di­ver­si­ty

 

I kicked off our European R&D summit last week with a conversation involving Novo Nordisk CEO Lars Fruergaard Jørgensen. Novo is aiming to launch a new era of obesity management with a new approval for semaglutide. And Jørgensen had a lot to say about what comes next in R&D, how they manage risk and gender diversity targets at the trendsetting European pharma giant.

John Carroll: I’m here with Lars Jørgensen, the CEO of Novo Nordisk. Lars, it’s been a really interesting year so far with Novo Nordisk, right? You’ve projected a new era of growing sales. You’ve been able to expand on the GLP-1 franchise that was already well established in diabetes now going into obesity. And I think a tremendous number of people are really interested in how that’s working out. You have forecast a growing amount of sales. We don’t know specifically how that might play out. I know a lot of the analysts have different ideas, how those numbers might play out, but that we are in fact embarking on a new era for Novo Nordisk in terms of what the company’s capable of doing and what it’s able to do and what it wants to do. And I wanted to start off by asking you about obesity in particular. Semaglutide has been approved in the United States for obesity. It’s an area of R&D that’s been very troubled for decades. There have been weight loss drugs that have come along. They’ve attracted a lot of attention, but they haven’t actually ever gained traction in the market. My first question is what’s different this time about obesity? What is different about this drug and why do you expect it to work now whereas previous drugs haven’t?

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Leen Kawas (L) has resigned as CEO of Athira and will be replaced by COO Mark Litton

Ex­clu­sive: Athi­ra CEO Leen Kawas re­signs af­ter in­ves­ti­ga­tion finds she ma­nip­u­lat­ed da­ta

Leen Kawas, CEO and founder of the Alzheimer’s upstart Athira Pharma, has resigned after an internal investigation found she altered images in her doctoral thesis and four other papers that were foundational to establishing the company.

Mark Litton, the company’s COO since June 2019 and a longtime biotech executive, has been named full-time CEO. Kawas, meanwhile, will no longer have ties to the company except for owning a few hundred thousand shares.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Pascal Soriot, AstraZeneca CEO (via Getty images)

UP­DAT­ED: FDA slaps As­traZeneca's MCL-1 can­cer drug with a hold af­ter safe­ty is­sue — 2 years af­ter Am­gen axed a trou­bled ri­val

There are new questions being posed about a class of cancer drugs in the wake of the second FDA-enforced clinical hold in the field.

Two years after the FDA hit Amgen with a clinical hold on its MCL-1 inhibitor AMG 397 following signs of cardiac toxicity, AstraZeneca says that regulators hit them with a hold on their rival therapy of the same class.

The pharma giant noted on clinicaltrials.gov that its Phase I/II study for the MCL-1 drug AZD5991 “has been put on hold to allow further evaluation of safety related information.”

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 120,300+ biopharma pros reading Endpoints daily — and it's free.

Sur­geons suc­cess­ful­ly at­tach pig kid­ney to a hu­man for the first time, us­ing tech from Unit­ed's Re­vivi­cor

In a first, researchers reportedly successfully transplanted a pig kidney into a human without triggering an immediate immune response this week. And the technology came from the biotech United Therapeutics.

Surgeons spent three days attaching the kidney to the patient’s blood vessels, but when all was said and done, the kidney appeared to be functioning normally in early testing, Reuters and the New York Times were among those to report. The kidney came from a genetically altered pig developed through United’s Revivicor unit.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 120,300+ biopharma pros reading Endpoints daily — and it's free.

Sen. Richard Durbin (D-IL, foreground) and Sen. Richard Blumenthal (D-CT) (Patrick Semansky/AP Images)

Sen­a­tors back FDA's plan to re­quire manda­to­ry pre­scriber ed­u­ca­tion for opi­oids

Three Senate Democrats are backing an FDA plan to require mandatory prescriber education for opioids as overdose deaths have risen sharply over the past decade, with almost 97,000 American opioid-related overdose deaths in the past year alone.

While acknowledging a decline in overall opioid analgesic dispensing in recent years, the FDA said it’s reconsidering the need for mandatory prescriber training through a REMS given the current situation with overdoses, and is seeking input on the aspects of the opioid crisis that mandatory training could potentially mitigate.